text.skipToContent text.skipToNavigation

PyroMark Q24 MDx

For IVD-validated mutation and methylation analysis using Pyrosequencing technology
  • Compliant with EU IVD Directive 98/79/EC
  • Reliable quantification of allele representation and methylation status
  • Sequence information enables discovery of rare mutations
  • More than one assay can be completed in a single run
  • 1–24 samples can be analyzed in as little as 15 minutes

The PyroMark Q24 MDx uses proven Pyrosequencing technology for real-time, sequence-based detection and quantification for in vitro diagnostic use in Europe. This innovative platform is highly suited for genotyping mutations, evaluating disease-related DNA methylation patterns, validating biomarkers, and other diagnostic-related assays.

The PyroMark Q24 MDx is intended for in vitro diagnostic use.



Features
Specifications
Altitude Up to 2000 m (6500 ft)
Applications Methylation analysis, allele quantification, genotyping, sequence analysis
CE/FDA/IVD compatible In Europe
Chemical resistance pH 4 to pH 9, common detergents, 0.5 M sodium hydroxide, ethanol
Connections One USB port (2.0)
Humidity Relative humidity of 20–90% (noncondensing)
Instrument dimensions 420 x 390 x 525 mm (16.5 x 15.4 x 20.7 in.)
Kits designed for this instrument IVD-labeled therascreen Kits
Operating temperature 15–32°C (59–90°F)
Overvoltage category II
Place of operation For indoor use only
Pollution level 2
Power 100–240 V AC, 47–63 Hz, 1.1–0.45 A (grounded). From external power supply to instrument: 12 VDC and 24 VDC nominal
Process temperature 28°C (82.4°F) ± 1°C
Process time Depends on the number of nucleotide dispensations (20 dispensations take 24 minutes)
Samples per run; throughput 1–24
Software PyroMark Q24 MDx Software 2.0
Technology Pyrosequencing
Weight 27.5 kg (60.6 lb)